Oncology

Ice Cube's BIG3 league and the PCF are deploying a new playbook, using basketball's cultural power to bring life-saving cancer screenings directly to Black men.

Komodo Health restructures its C-suite, signaling a major shift in healthcare. It's no longer about AI hype; it's about enterprise-scale dominance.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

A new corporate alliance is targeting veteran lung disease. It’s more than a webinar; it’s a strategic response to the PACT Act’s seismic shift.

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.

Apollo Athenaa's new handbook addresses caregiver burnout, offering a vital resource to the unsung heroes of India's growing cancer crisis.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

Pharma giant MSD and health-tech innovator Nivi are using an AI chatbot to fight cervical cancer in Asia. Can this model overcome regulatory hurdles and scale?

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Strive Health's new CMO and CFO hires signal a strategic acceleration in value-based kidney care, blending clinical innovation with financial AI deployment.

German firm NVision wins a top award for POLARIS, a quantum-enhanced MRI platform that shows if cancer therapy is working weeks or months sooner.

Renowned cancer researcher Dr. Morag Park takes the helm at the Gairdner Foundation, a key predictor of Nobel Prizes. What does this strategic move mean for global science?

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.